Receptor Life Sciences
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Receptor Life Sciences
Finance Watch: Tessera Secures $300m-Plus To Write New Genes
Private Company Edition: In other venture capital mega-rounds, Aurion brought in $120m, Sionna launched with $111m and Irish firm Renexxion said a private equity group committed up to $100m in total investment to be made within 36 months of a future public listing.
Finance Watch: Investors Can't Get Enough Of NASH, Including Start-Ups With Novel Drugs
Terns raised an $80m Series B round for NASH and cancer programs, while 89Bio launched with a $60m Series A to fund drugs for NASH and other liver and metabolic diseases. Also, Stoke leads recent VC deals with $90m Series B.
IN VIVO’s Deals Of The Month: January 2016
IN VIVO’s editors pick January's top alliance, financing and M&A deals (free with registration).
Deal Watch: Acorda Places Another Bet In Neurology With Biotie Tender
Following the dissolution of its partnership with Sanofi, MannKind's next gambit is licensing its dry-powder delivery technology to new company Receptor Life Sciences. We also highlight our sister publication IN VIVO's deal of the year winners in the alliance, M&A and financing categories.
- Medical Devices
- Drug Delivery
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.